-
Phase 3
-
-
4-18Age Range
-
37Locations
-
Recruiting
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
You're about to leave bmsclinicaltrials.com
This link takes you to a website of Bristol Myers Squibb that may have a different purpose, may have different terms and conditions, and is being provided solely to enable you to contact Bristol Myers Squibb.
You're about to leave bmsclinicaltrials.com
This link takes you to a website of Bristol Myers Squibb that may have a different purpose, may have different terms and conditions, and is being provided solely to enable you to contact Bristol Myers Squibb.
You are about to leave bmsclinicaltrials.com. The site you are linking to is not controlled or endorsed by Bristol Myers Squibb and Bristol Myers Squibb is not responsible for the content provided on that site.
You are about to leave bmsclinicaltrials.com. The site you are linking to is not controlled or endorsed by Bristol Myers Squibb and Bristol Myers Squibb is not responsible for the content provided on that site.
You are about to leave bmsclinicaltrials.com. The site you are linking to is not controlled or endorsed by Bristol Myers Squibb and Bristol Myers Squibb is not responsible for the content provided on that site.
You are about to leave bmsclinicaltrials.com. The site you are linking to is not controlled or endorsed by Bristol Myers Squibb and Bristol Myers Squibb is not responsible for the content provided on that site.
You are about to leave bmsclinicaltrials.com. The site you are linking to is not controlled or endorsed by Bristol Myers Squibb and Bristol Myers Squibb is not responsible for the content provided on that site.
Recruiting
A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Pediatric Participants With Moderate to Severe Plaque Psoriasis
The purpose of this pediatric study is to evaluate the drug levels, efficacy and safety
of Deucravacitinib in pediatric participants aged 4 to <18 years with moderate to severe
plaque psoriasis. This study includes two cohorts; Cohort 1 (age 12 to <18 years) and
Cohort 2 (age 4 to <12 years), with two parts; for each cohort. Part A will evaluate the
drug lev...Read More
els of BMS-986165 to enable selection of 2 dose levels to be studied in Part B.
Part B will assess the efficacy and safety of two dose levels in pediatric participants
with moderate to severe plaque psoriasis. The 5-year long-term extension (LTE) period
will observe the long-term safety and tolerability of deucravacitinib in pediatric
participants with psoriasis who have completed Parts A or B of the study.Read Less
Experimental: Active treatment deucravacitinib half-standard dose
Experimental: Active treatment deucravacitinib standard dose
Placebo Comparator: Placebo